Testing a diabetes self-management video game in adults with type 2 diabetes
Tests the SugarVita 2.0 game in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Twelve-Week Pilot Study Evaluating the Usability and Preliminary Effects of SugarVita 2.0 in Adults With Type 2 Diabetes
Key facts
- Where
- Eindhoven, NetherlandsSee the site
Where in Netherlands
- Maxima Medical CentreEindhoven, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Maxima Medical Center
- Trial code
- NCT07812623
- Record updated
- 10 September 2026
- Original description
Diabetes self-management education is essential for achieving optimal glycemic control, but conventional education does not meet the needs of all patients. SugarVita 2.0 is a serious digital game designed to improve diabetes self-management through interactive gameplay and a semi-personalized glucose simulator. This multicenter, single-arm, 12-week pilot study will evaluate the usability of SugarVita 2.0 and its effects on diabetes self-management, self-confidence, diabetes-related distress, diabetes knowledge, HbA1c, and user engagement in adults with type 2 diabetes.Read full original descriptionShow less
SugarVita 2.0: Confirmation of a Serious Game for Self-management of Diabetes
Diabetes self-management education is essential for achieving optimal glycemic control, but conventional education does not meet the needs of all patients. SugarVita 2.0 is a serious digital game designed to improve diabetes self-management through interactive gameplay and a semi-personalized glucose simulator. This multicenter, single-arm, 12-week pilot study will evaluate the usability of SugarVita 2.0 and its effects on diabetes self-management, self-confidence, diabetes-related distress, diabetes knowledge, HbA1c, and user engagement in adults with type 2 diabetes.
Inclusion: Adults aged 18 years or older; Diagnosis of type 2 diabetes mellitus (T2DM); Written informed consent obtained before any study procedures; HbA1c >55 mmol/mol prior to study participation; For participants with T2DM only: BMI >25 kg/m²; Sufficient command of the Dutch language to complete study questionnaires.
Exclusion: Active malignancy, except adequately treated basal cell carcinoma or squamous cell carcinoma of the skin; Pregnancy or breastfeeding.